Summary

Market Overview
The Global Protein Therapeutics Market was valued at USD 271.26 billion in 2024 and is expected to reach USD 403.23 billion by 2030, growing at a CAGR of 6.80% during the forecast period. Protein therapeutics encompasses a broad range of medical treatments using proteins or peptides to treat, prevent, or diagnose diseases. These therapeutic agents may be naturally derived, genetically engineered, or synthetically produced, offering targeted and highly specific treatment approaches. Produced through techniques like recombinant DNA technology and bioprocessing, protein therapeutics are known for their high specificity and minimal off-target effects compared to traditional small-molecule drugs. With ongoing innovations in protein engineering, such as antibody-drug conjugates and bispecific antibodies, the therapeutic potential of proteins continues to expand. The growing global burden of age-related diseases, including cardiovascular and autoimmune disorders, is fueling demand for these advanced therapies. Additionally, the rise in biosimilars, advances in genomics, and healthcare expansion in developing economies are contributing to market growth by improving treatment accessibility and personalization.
Key Market Drivers
Advancements in Protein Engineering
Protein engineering technologies have greatly expanded the potential of therapeutic proteins. Techniques such as directed evolution replicate natural selection in the lab to generate optimized proteins with improved stability, activity, or specificity. Computational modeling and rational design allow researchers to predict structural and functional changes in proteins, accelerating development. In 2025, Capgemini launched a generative AI-driven method using a protein large language model (pLLM) to predict optimal protein variants—highlighting the convergence of biotechnology and AI. Innovations in antibody engineering have produced monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), which provide targeted and potent treatment options. Fusion proteins, combining functional protein domains, enhance half-life and therapeutic action. These advances enable the creation of tailored therapies for oncology, immunology, and rare diseases, driving demand across healthcare sectors.
Key Market Challenges
Manufacturing Complexities
Protein therapeutics require highly controlled and complex manufacturing environments. These biologics must maintain specific three-dimensional structures, undergo correct folding, and have precise post-translational modifications. Cell-based systems such as CHO cells are commonly used, but developing and optimizing these systems can be labor-intensive and time-consuming. Upstream processing, including cell culture, must manage strict parameters, while downstream purification processes require multiple steps to ensure purity and remove contaminants. Quality assurance demands advanced analytical tools to verify protein identity and potency. Scaling up production from lab to commercial levels introduces additional challenges in maintaining consistency and regulatory compliance. Variability in regional manufacturing and stringent GMP guidelines further complicate global operations. These complexities underscore the high cost and technical barriers in producing protein-based therapies.
Key Market Trends
Growth in Green and Energy-Efficient Elevators
(Not applicable for this section. Replaced with relevant trend below.)
Rise of Personalized and Precision Protein Therapies
The integration of genomics, biomarker profiling, and next-generation sequencing is fueling the growth of personalized protein therapeutics. These approaches allow the development of drugs tailored to specific genetic or molecular profiles, enhancing treatment effectiveness and reducing adverse effects. Biopharmaceutical companies are investing in precision biologics for conditions such as cancer, autoimmune disorders, and metabolic diseases. Immunotherapies—including CAR-T cells and immune checkpoint inhibitors—are leading the way, supported by robust clinical research and increasing regulatory approvals. Additionally, biosimilars are gaining traction by offering cost-effective alternatives to originator biologics, expanding access in cost-sensitive markets. This trend toward individualized treatment strategies is reshaping the therapeutic landscape and aligning with global healthcare goals to improve outcomes and reduce system-wide costs.
Key Market Players
• Amgen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc
• Teva Pharmaceutical Industries Ltd
• Bristol-Myers Squibb Company
• AbbVie Inc.
Report Scope:
In this report, the Global Protein Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Protein Therapeutics Market, By Protein Function:
o Enzymatic & Regulatory
o Protein Diagnostics
o Vaccines
• Protein Therapeutics Market, By Product Type:
o Blood Clotting Factor
o Erythropoietin
o Follicle Stimulating Hormone
o G-CSF
o Insulin
o Interferons
o Monoclonal Antibodies
• Protein Therapeutics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Asia-Pacific
§ China
§ India
§ South Korea
§ Australia
§ Japan
o Europe
§ Germany
§ France
§ United Kingdom
§ Spain
§ Italy
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Protein Therapeutics Market.
Available Customizations:
Global Protein Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Protein Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines)
5.2.2. By Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. Asia Pacific Protein Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Protein Function
6.2.2. By Product Type
6.2.3. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Protein Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Protein Function
6.3.1.2.2. By Product Type
6.3.2. India Protein Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Protein Function
6.3.2.2.2. By Product Type
6.3.3. Australia Protein Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Protein Function
6.3.3.2.2. By Product Type
6.3.4. Japan Protein Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Protein Function
6.3.4.2.2. By Product Type
6.3.5. South Korea Protein Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Protein Function
6.3.5.2.2. By Product Type
7. Europe Protein Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Protein Function
7.2.2. By Product Type
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Protein Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Protein Function
7.3.1.2.2. By Product Type
7.3.2. Germany Protein Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Protein Function
7.3.2.2.2. By Product Type
7.3.3. Spain Protein Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Protein Function
7.3.3.2.2. By Product Type
7.3.4. Italy Protein Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Protein Function
7.3.4.2.2. By Product Type
7.3.5. United Kingdom Protein Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Protein Function
7.3.5.2.2. By Product Type
8. North America Protein Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Protein Function
8.2.2. By Product Type
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Protein Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Protein Function
8.3.1.2.2. By Product Type
8.3.2. Mexico Protein Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Protein Function
8.3.2.2.2. By Product Type
8.3.3. Canada Protein Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Protein Function
8.3.3.2.2. By Product Type
9. South America Protein Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Protein Function
9.2.2. By Product Type
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Protein Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Protein Function
9.3.1.2.2. By Product Type
9.3.2. Argentina Protein Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Protein Function
9.3.2.2.2. By Product Type
9.3.3. Colombia Protein Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Protein Function
9.3.3.2.2. By Product Type
10. Middle East and Africa Protein Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Protein Function
10.2.2. By Product Type
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Protein Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Protein Function
10.3.1.2.2. By Product Type
10.3.2. Saudi Arabia Protein Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Protein Function
10.3.2.2.2. By Product Type
10.3.3. UAE Protein Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Protein Function
10.3.3.2.2. By Product Type
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Protein Therapeutics Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Amgen Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Eli Lilly and Company.
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. F. Hoffmann-La Roche Ltd
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. Johnson & Johnson Services, Inc.
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. Merck KGaA
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Pfizer Inc.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. AstraZeneca Plc.
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. Teva Pharmaceutical Industries Ltd
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. AbbVie Inc.
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.Bristol-Myers Squibb Company
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer